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We investigated antimicrobial drug resistance in ocular 
Chlamydia trachomatis 18 months after 4 biannual commu-
nitywide distributions of antimicrobial drugs in a region of 
Ethiopia where ocular strains of C. trachomatis are highly 
endemic. We found no significant differences in susceptibili-
ties to azithromycin and doxycycline in 6 posttreatment and 
4 pretreatment samples.
T
rachoma, a sequela of repeated conjunctival infection 
with Chlamydia trachomatis, is the leading cause of 
infectious blindness (1). To control endemic trachoma, the 
World Health Organization (WHO) recommends commu-
nitywide distribution of antimicrobial agents, along with 
surgery and improved hygiene. Mass azithromycin treat-
ments have been effective in reducing this infection (2). 
However, concerns have been raised that selective antimi-
crobial pressure may produce macrolide-resistant strains of 
C. trachomatis and other pathogens (3).
Solomon et al. reported on antimicrobial drug suscep-
tibility in 9 chlamydial isolates 2 months after mass an-
timicrobial drug treatment in Tanzania (4). These authors 
observed a slight increase in the median MIC after treat-
ment but found no resistant strains. Despite this encourag-
ing study, investigations of the long-term impact of mul-
tiple  treatments  on  antimicrobial  drug  susceptibility  are 
needed. Geographic areas where trachoma is hyperendemic 
require repeated mass distributions because infection has 
been shown to return after a single treatment (5). Antimi-
crobial  drug–resistant  C.  trachomatis  might  not  emerge 
until multiple treatments have occurred. For example, in 
Nepal, azithromycin-resistant pneumococcal strains were 
observed only after consecutive annual treatments (3). The 
selective pressure of repeated azithromycin distributions 
might enable rapid expansion of resistant clones (6). In 
2006, we investigated antimicrobial drug resistance in ocu-
lar C. trachomatis 18 months after 4 biannual treatments 
(2003–2004) in a trachoma-endemic region of Ethiopia.
The Study
We  obtained  ethical  approval  from  the  Committee 
on Human Research at the University of California, San 
Francisco (UCSF), and from the National Ethical Clear-
ance Committee of the Ethiopian Science and Technology 
Agency. Antimicrobial treatments were distributed every 6 
months to 24 randomly selected villages in the Gurage zone 
in Ethiopia. Persons >1 year of age were offered single-dose 
oral azithromycin (1 g for adults or 20 mg/kg for children) 
as directly observed treatment. Pregnant women and those 
allergic to macrolides were offered a 6-week course of topi-
cal 1% tetracycline ointment (applied 2×/day to both eyes, 
not directly observed). At each biannual visit, 8 villages 
not yet receiving antimicrobial distribution were randomly 
selected from the same district to serve as controls (5). The 
same procedures were conducted in the control villages 
as in the treatment villages. After completion of clinical 
ocular examinations and sample collection, treatment was   
offered to study and control villages.
All children 1–5 years of age received ocular examina-
tions, and conjunctival swabs were taken from their right 
tarsal  conjunctiva  before  treatment.  Swabs  were  placed 
immediately in M4RT media (Remel, Lenexa, KS, USA) 
at 4°C, frozen at –20°C within 6 hours, and transported at 
4°C to the microbiology laboratory at the Proctor Founda-
tion at UCSF, where they were stored at –80°C until PCR 
was performed. An aliquot of each sample was processed 
with the Amplicor PCR test (Roche Molecular Systems, 
Branchburg, NJ, USA) for detection of C. trachomatis. At 
18 months after the fourth biannual treatment, the preva-
lence of ocular infection in preschool children was 10.7% 
(95% confidence interval [CI] 5.5%–19.3%) (7). In control 
villages that had not yet received treatment, the average 
prevalence was 31.2% (95% CI 23.1%–40.5%). Of 552 
samples from 8 biannually treated villages, 59 were posi-
tive by PCR. Of 523 samples from 8 control villages, 163 
were PCR positive. Among these PCR-positive samples, 
10 were randomly chosen from biannually treated villag-
es and 10 from control villages. Remnants of the original 
specimens were sent to the UCSF Chlamydia Laboratory 
for culture and antimicrobial susceptibility testing.
Technicians were unaware of the origin of each sample, 
and the order in which samples were tested was random-
ized. C. trachomatis isolation was carried out in cyclohex-
imide-treated McCoy cells in 1-dram shell vials by using a 
modification of the procedure of Ripa and Mardh (8). We 
sequenced the ompA gene from all conjunctival isolates (9). 
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The protocol for determining antimicrobial drug sensitiv-
ity (10) was used with minor modifications. Azithromy-
cin (American Pharmaceutical Partners, Schaumburg, IL, 
USA)  and  doxycycline  (Bedford  Laboratories,  Bedford, 
OH, USA) were tested against chlamydia isolates; MICs 
were conducted in triplicate, and minimum chlamydicidal 
concentrations (MCCs) in duplicate. Each MIC or MCC in-
cluded a clinical chlamydia isolate with a known suscepti-
bility to azithromycin and doxycycline as a positive control 
to ensure the validity of the sensitivity testing.
Among 10 Amplicor PCR–positive samples random-
ly chosen from biannually treated villages, cultures for 7 
samples were positive; 6 of these were tested for resistance 
against azithromycin and doxycycline (Table). Of 10 ran-
dom Amplicor PCR–positive samples from pretreatment 
villages, cultures for 6 were positive; 4 of these samples 
were tested for resistance (Table).
MICs and MCCs were comparable between biannually 
treated villages and control villages for the 2 antimicrobial 
drugs tested. No statistically significant differences were 
found (p = 0.76 for azithromycin MIC; p = 1.00 for azithro-
mycin MCC; p = 0.22 for doxycycline MIC; and p = 0.45 
for doxycycline MCC) (Wilcoxon rank-sum test, STATA, 
StataCorp, College Station, TX, USA). With the number 
of samples tested (6 posttreatment samples and 4 pretreat-
ment samples), we had 95% power to detect a 2-fold shift 
in the mean MIC (α = 0.05, two-sided) and 90% power to 
detect a 2-fold shift in the mean MCC of azithromycin. For 
doxycycline, we had 99% power to detect a 2-fold change 
in the mean MIC (α = 0.05, two-sided) and 85% power to 
detect a 2-fold change in the mean MCC.
Conclusions
This study found no significant increase in antimicro-
bial drug resistance against azithromycin or doxycycline 
after treatment for ocular C. trachomatis. Our study had 
limited power to detect a rare mutation that can engender 
resistant chlamydia strains but sufficient power to detect 
a major shift in antimicrobial susceptibilities. In a region 
like Ethiopia, where trachoma is endemic, infection often 
returns to the community after mass distribution of antimi-
crobial drugs stops (7). Concerns exist that resistant strains 
may result in failure to eliminate trachoma locally, but our 
study refutes this concern. The lack of antimicrobial drug 
resistance shown in this study is particularly encouraging 
because the region was subjected to higher selective pres-
sures  from  biannual  treatments  than  would  be  expected 
from annual treatments recommended by WHO.
Chlamydiae are obligate intracellular bacteria that can 
multiply only in the cytoplasm of a susceptible host cell, 
and acquisition of antimicrobial resistance genes from oth-
er organisms through horizontal transfer is probably rare. 
In vitro spontaneous mutations in chlamydia can confer an-
timicrobial resistance, including that in the 23S rRNA, but 
mutations appear to incur competitive disadvantages (11). 
The persistent pressure of repeated mass treatments 
may select for compensatory mutations that could adapt 
chlamydia to the fitness cost of the initial mutation (11). 
This  scenario  would  enable  the  expansion  of  resistant 
strains after communitywide distribution of azithromycin 
in trachoma control programs. However, after treatment is 
discontinued, sensitive wild type strains may outcompete 
resistant ones. In one Australian community, the increased 
population  of  azithromycin-resistant  pneumococcus  was 
quickly replaced by sensitive strains after treatment ceased 
(6). In our study, if resistant strains emerged after 4 biannu-
al antimicrobial treatments, they did not survive the compe-
tition with sensitive strains 18 months after mass treatment 
stopped.
Determining antimicrobial resistance in C. trachoma-
tis is technically challenging, has no standardized protocol 
(12), and is rarely pursued. DNA sequencing to identify 
genetic mutations that confer macrolide resistance could be 
more sensitive but would require further efforts to char-
acterize specific mutations causing macrolide resistance. 
Mass distribution of antimicrobial drugs, especially azithro-
mycin, is a critical component in the global elimination of 
blinding trachoma. Emergence of antimicrobial drug resis-
tance to chlamydia treatments would be detrimental to the 
goal of eliminating trachoma, so surveillance for resistance 
should be part of trachoma programs.
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Table. Antimicrobial drug susceptibilities of Chlamydia
trachomatis, Ethiopia* 
Azithromycin†  Doxycycline†  Treatment 
status Serotype  MIC MCC MIC MCC
4 biannual A/Har13 0.5 0.5 0.03 0.03
Ba/Apache-2 0.5 0.5 0.03 0.03
Ba/Apache-2 0.5 0.5 0.03 0.06
Ba/Apache-2 0.25 0.5 0.03 0.06
Ba/Apache-2 0.5 0.5 0.03 0.06
Ba/Apache-2 0.5 0.5 0.03 0.03
None A/Har 13  0.5 0.5 0.03 0.03
A/Har 13 0.5 0.5 0.03 0.03
A/Har 13 0.5 1 0.015 0.06
Ba/Apache-2 0.25 0.25 0.03 0.03
*Samples taken in 2006, 18 months after 4 biannual treatments in 2003–
2004. MCC, minimum chlamydicidal concentration. 
†MIC and MCC values given in Pg/mL.
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